Cargando…

Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years

BACKGROUND: A decrease in breast density due to tamoxifen preventive therapy might indicate greater benefit from the drug. It is not known whether mammographic density continues to decline after 1 year of therapy, or whether measures of breast density change are sufficiently stable for personalised...

Descripción completa

Detalles Bibliográficos
Autores principales: Brentnall, Adam R., Warren, Ruth, Harkness, Elaine F., Astley, Susan M., Wiseman, Julia, Fox, Jill, Fox, Lynne, Eriksson, Mikael, Hall, Per, Cuzick, Jack, Evans, D. Gareth, Howell, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523310/
https://www.ncbi.nlm.nih.gov/pubmed/32993747
http://dx.doi.org/10.1186/s13058-020-01340-4
_version_ 1783588361160622080
author Brentnall, Adam R.
Warren, Ruth
Harkness, Elaine F.
Astley, Susan M.
Wiseman, Julia
Fox, Jill
Fox, Lynne
Eriksson, Mikael
Hall, Per
Cuzick, Jack
Evans, D. Gareth
Howell, Anthony
author_facet Brentnall, Adam R.
Warren, Ruth
Harkness, Elaine F.
Astley, Susan M.
Wiseman, Julia
Fox, Jill
Fox, Lynne
Eriksson, Mikael
Hall, Per
Cuzick, Jack
Evans, D. Gareth
Howell, Anthony
author_sort Brentnall, Adam R.
collection PubMed
description BACKGROUND: A decrease in breast density due to tamoxifen preventive therapy might indicate greater benefit from the drug. It is not known whether mammographic density continues to decline after 1 year of therapy, or whether measures of breast density change are sufficiently stable for personalised recommendations. METHODS: Mammographic density was measured annually over up to 5 years in premenopausal women with no previous diagnosis of breast cancer but at increased risk of breast cancer attending a family-history clinic in Manchester, UK (baseline 2010-2013). Tamoxifen (20 mg/day) for prevention was prescribed for up to 5 years in one group; the other group did not receive tamoxifen and were matched by age. Fully automatic methods were used on mammograms over the 5-year follow-up: three area-based measures (NN-VAS, Stratus, Densitas) and one volumetric (Volpara). Additionally, percentage breast density at baseline and first follow-up mammograms was measured visually. The size of density declines at the first follow-up mammogram and thereafter was estimated using a linear mixed model adjusted for age and body mass index. The stability of density change at 1 year was assessed by evaluating mean squared error loss from predictions based on individual or mean density change at 1 year. RESULTS: Analysis used mammograms from 126 healthy premenopausal women before and as they received tamoxifen for prevention (median age 42 years) and 172 matched controls (median age 41 years), with median 3 years follow-up. There was a strong correlation between percentage density measures used on the same mammogram in both the tamoxifen and no tamoxifen groups (all correlation coeficients > 0.8). Tamoxifen reduced mean breast density in year 1 by approximately 17–25% of the inter-quartile range of four automated percentage density measures at baseline, and from year 2, it decreased further by approximately 2–7% per year. Predicting change at 2 years using individual change at 1 year was approximately 60–300% worse than using mean change at 1year. CONCLUSIONS: All measures showed a consistent and large average tamoxifen-induced change in density over the first year, and a continued decline thereafter. However, these measures of density change at 1 year were not stable on an individual basis.
format Online
Article
Text
id pubmed-7523310
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-75233102020-09-30 Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years Brentnall, Adam R. Warren, Ruth Harkness, Elaine F. Astley, Susan M. Wiseman, Julia Fox, Jill Fox, Lynne Eriksson, Mikael Hall, Per Cuzick, Jack Evans, D. Gareth Howell, Anthony Breast Cancer Res Research Article BACKGROUND: A decrease in breast density due to tamoxifen preventive therapy might indicate greater benefit from the drug. It is not known whether mammographic density continues to decline after 1 year of therapy, or whether measures of breast density change are sufficiently stable for personalised recommendations. METHODS: Mammographic density was measured annually over up to 5 years in premenopausal women with no previous diagnosis of breast cancer but at increased risk of breast cancer attending a family-history clinic in Manchester, UK (baseline 2010-2013). Tamoxifen (20 mg/day) for prevention was prescribed for up to 5 years in one group; the other group did not receive tamoxifen and were matched by age. Fully automatic methods were used on mammograms over the 5-year follow-up: three area-based measures (NN-VAS, Stratus, Densitas) and one volumetric (Volpara). Additionally, percentage breast density at baseline and first follow-up mammograms was measured visually. The size of density declines at the first follow-up mammogram and thereafter was estimated using a linear mixed model adjusted for age and body mass index. The stability of density change at 1 year was assessed by evaluating mean squared error loss from predictions based on individual or mean density change at 1 year. RESULTS: Analysis used mammograms from 126 healthy premenopausal women before and as they received tamoxifen for prevention (median age 42 years) and 172 matched controls (median age 41 years), with median 3 years follow-up. There was a strong correlation between percentage density measures used on the same mammogram in both the tamoxifen and no tamoxifen groups (all correlation coeficients > 0.8). Tamoxifen reduced mean breast density in year 1 by approximately 17–25% of the inter-quartile range of four automated percentage density measures at baseline, and from year 2, it decreased further by approximately 2–7% per year. Predicting change at 2 years using individual change at 1 year was approximately 60–300% worse than using mean change at 1year. CONCLUSIONS: All measures showed a consistent and large average tamoxifen-induced change in density over the first year, and a continued decline thereafter. However, these measures of density change at 1 year were not stable on an individual basis. BioMed Central 2020-09-29 2020 /pmc/articles/PMC7523310/ /pubmed/32993747 http://dx.doi.org/10.1186/s13058-020-01340-4 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Brentnall, Adam R.
Warren, Ruth
Harkness, Elaine F.
Astley, Susan M.
Wiseman, Julia
Fox, Jill
Fox, Lynne
Eriksson, Mikael
Hall, Per
Cuzick, Jack
Evans, D. Gareth
Howell, Anthony
Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years
title Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years
title_full Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years
title_fullStr Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years
title_full_unstemmed Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years
title_short Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years
title_sort mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523310/
https://www.ncbi.nlm.nih.gov/pubmed/32993747
http://dx.doi.org/10.1186/s13058-020-01340-4
work_keys_str_mv AT brentnalladamr mammographicdensitychangeinacohortofpremenopausalwomenreceivingtamoxifenforbreastcancerpreventionover5years
AT warrenruth mammographicdensitychangeinacohortofpremenopausalwomenreceivingtamoxifenforbreastcancerpreventionover5years
AT harknesselainef mammographicdensitychangeinacohortofpremenopausalwomenreceivingtamoxifenforbreastcancerpreventionover5years
AT astleysusanm mammographicdensitychangeinacohortofpremenopausalwomenreceivingtamoxifenforbreastcancerpreventionover5years
AT wisemanjulia mammographicdensitychangeinacohortofpremenopausalwomenreceivingtamoxifenforbreastcancerpreventionover5years
AT foxjill mammographicdensitychangeinacohortofpremenopausalwomenreceivingtamoxifenforbreastcancerpreventionover5years
AT foxlynne mammographicdensitychangeinacohortofpremenopausalwomenreceivingtamoxifenforbreastcancerpreventionover5years
AT erikssonmikael mammographicdensitychangeinacohortofpremenopausalwomenreceivingtamoxifenforbreastcancerpreventionover5years
AT hallper mammographicdensitychangeinacohortofpremenopausalwomenreceivingtamoxifenforbreastcancerpreventionover5years
AT cuzickjack mammographicdensitychangeinacohortofpremenopausalwomenreceivingtamoxifenforbreastcancerpreventionover5years
AT evansdgareth mammographicdensitychangeinacohortofpremenopausalwomenreceivingtamoxifenforbreastcancerpreventionover5years
AT howellanthony mammographicdensitychangeinacohortofpremenopausalwomenreceivingtamoxifenforbreastcancerpreventionover5years